Bibliographic Details
| Title: |
Clinical predictors of physiologic change after treatment with immunosuppression in hypersensitivity pneumonitis. |
| Authors: |
Kypreos, Margaret1 (AUTHOR) margaret.kypreos@utsouthwestern.edu, de Boer, Esther2 (AUTHOR), Ellington, Graham1 (AUTHOR), Fujioka, Genichiro3 (AUTHOR), Liu, Jerry3 (AUTHOR), Glazer, Craig1 (AUTHOR), Adams, Traci1 (AUTHOR) |
| Source: |
PLoS ONE. 11/25/2024, Vol. 19 Issue 11, p1-9. 9p. |
| Subject Terms: |
*HYPERSENSITIVITY pneumonitis, *INTERSTITIAL lung diseases, *VITAL capacity (Respiration), *BIOMARKERS, *IMMUNOSUPPRESSIVE agents, *IODINE isotopes |
| Abstract: |
Introduction: Treatment of hypersensitivity pneumonitis involves removal of the antigen and may include the use of immunosuppression or antifibrotic therapy. It remains unclear whether antifibrotic or immunosuppressive therapy is more beneficial in fibrotic hypersensitivity pneumonitis or if clinical markers can predict a patient's response to therapy. Methods: We evaluated a retrospective cohort in order to determine if certain clinical characteristics can predict physiologic improvement with immunosuppressive treatment in patients with chronic hypersensitivity pneumonitis. Patients with a diagnosis of hypersensitivity pneumonitis with a moderate, high, or definite confidence according to the American Thoracic Society criteria were included in the study. Results: Overall immunosuppression did not lead to improvement in % predicted forced vital capacity (FVC%) and % predicted diffusion capacity (DLCO%). Patients with fibrotic hypersensitivity pneumonitis and those with familial interstitial lung disease demonstrated a decline in FVC% predicted as well as DLCO% predicted over one year and the use of immunosuppression does not modify that risk. In contrast, patients with extensive ground glass demonstrated improvement in DLCO% predicted but not FVC% predicted over one year with or without the use of immunosuppression. Conclusion: Our study demonstrates that certain radiographic variables trend toward a significant impact on FVC% predicted as well as DLCO% predicted and suggests that antifibrotic therapy may be a better initial choice of therapy in patients with fibrotic hypersensitivity pneumonitis as decline occurred with or without the use of immunosuppression. [ABSTRACT FROM AUTHOR] |
|
Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
